India, Oct. 8 -- Montana could provide Indian biotechnology and biopharma companies with an alternative pathway to reach US patients, generate clinical experience and build data while progressing towards wider regulatory approval, said Steve Eror, President, Montana Bioscience Alliance and CEO, Solo-Dex.

Speaking at the CXO-level roundtable facilitated by the Association of Biotechnology Led Enterprises (ABLE) during Montana Governor Greg Gianforte's India visit to Bengaluru on October 7, Eror outlined Montana's experimental treatment and Right to Try framework, which he said could be particularly relevant for emerging therapies, personalised medicine and advanced treatments.

Eror said the objective was to bring together India's capabil...